Ann: Q2 FY24 MDR Quarterly Update, page-4

How do other healthcare stocks with significantly less revenues, less QoQ growth and less cash hold their market caps and maintain shareholder interest?

The view count on this announcement from yesterday is 553.

ALC announce their 4C and there's almost 4000 views in a few hours.

M7T post a 5% increase in HY revenues to $26.8M and have a market cap of $166M.

MDR announce $50M revenue for Q2 and the needle doesn't move, in fact some selling pressure.

Agree with your assessment SS, Management need to crank out $40M+ revenues for H2.

This is quite achievable looking at the trajectory and consistent double digit revenue growth.

Outgoings this quarter ($26.8M) much larger than the previous December quarter ($19.8M).

They state cloud and marketing costs attributing to the increase.

Hopefully the marketing turns into revenue.

It's not clear to me if we've transacted any of the £1M for Charac yet?

AU revenues will increase with the NQ pilot program starting in March and running until EOFY25.

With this update we're in Siberia now with announcements throughout 2023 mostly being mandatory reports (AGM, Governance, Director Notices, Employee Securities) and management personnel changes.

The only "new news" was the North Queensland pilot awarded in November.

I wouldn't consider announcing the pilot commencing on March 1 as "new news", so hoping Management can keep the momentum with some "new new news".